Use of Fish Oils to Reduce Recurrence of Atrial Fibrillation Following DC Cardioversion

The recruitment status of this study is unknown because the information has not been verified recently.

Verified October 2005 by Melbourne Health.
Recruitment status was Recruiting

Sponsor:

Information provided by:

Melbourne Health

ClinicalTrials.gov Identifier:

NCT00232219

First received: October 2, 2005

Last updated: NA

Last verified: October 2005

History: No changes posted

Tracking Information

First Received Date ^ICMJE

October 2, 2005

Last Updated Date

October 2, 2005

Start Date ^ICMJE

Not Provided

Primary Completion Date

Not Provided

Current Primary Outcome Measures ^ICMJE

Not Provided

Original Primary Outcome Measures ^ICMJE

Not Provided

Change History

No Changes Posted

Current Secondary Outcome Measures ^ICMJE

Not Provided

Original Secondary Outcome Measures ^ICMJE

Not Provided

Current Other Outcome Measures ^ICMJE

Not Provided

Original Other Outcome Measures ^ICMJE

Not Provided

Descriptive Information

Brief Title ^ICMJE

Use of Fish Oils to Reduce Recurrence of Atrial Fibrillation Following DC Cardioversion

Official Title ^ICMJE

Use of Fish Oils to Reduce Recurrence of Atrial Fibrillation Following DC Cardioversion.

Brief Summary

The purpose of this study is to investigate whether fish oil supplements may be beneficial in preventing the recurrence of atrial fibrillation after cardioversion.

Atrial fibrillation is a heart condition which can sometimes be successfully treated by a cardioversion.

Cardioversion involves resetting the heart back to normal with the use of electric current.

There is a tendency for the atrial fibrillation to recur , days weeks or even months after the cardioversion.

Fish oil supplements may be of benefit to patients with heart problems Recent evidence suggests that fish oils may be beneficial to patients with rhythm disturbances.

Detailed Description

Not Provided

Study Type ^ICMJE

Interventional

Study Phase

Not Provided

Study Design ^ICMJE

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind

Condition ^ICMJE

Atrial Fibrillation

Intervention ^ICMJE

Drug: Fish oil

Study Arm (s)

Not Provided

Publications *

Not Provided

* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.

Recruitment Information

Recruitment Status ^ICMJE

Recruiting

Enrollment ^ICMJE

Not Provided

Completion Date

Not Provided

Primary Completion Date

Not Provided

Eligibility Criteria ^ICMJE

Inclusion Criteria:

Patients with persistent Atrial Fibrillation on Warfarin.

Exclusion Criteria:

paroxysmal atrial fibrillation with self terminating episodes.
left atrial size>6.0cm
myocardial infarction in the previous 6 months.
contraindications to amiodarone use .
cardiac surgery in the previous 3 months .
an acute reversible illness contributing to the development of af
a QTc interval > 480ms.
pregnancy

Gender

Both

Ages

18 Years to 80 Years

Accepts Healthy Volunteers

Yes

Contacts ^ICMJE

Contact: Paul Sparks, MBBS,PhD, FRACP

0393427000 ext 27133

paul.sparks@mh.org.au

Location Countries ^ICMJE

Australia

Administrative Information

NCT Number ^ICMJE

NCT00232219

Other Study ID Numbers ^ICMJE

2003.188

Has Data Monitoring Committee

Not Provided

Responsible Party

Not Provided

Study Sponsor ^ICMJE

Melbourne Health

Collaborators ^ICMJE

Not Provided

Investigators ^ICMJE

Principal Investigator:

Paul Sparks, MBBS, PhD. FRACP

Melbourne Health

Information Provided By

Melbourne Health

Verification Date

October 2005

^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP

To Top